0000000000648445

AUTHOR

Juergen Jauernig

showing 2 related works from this author

Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and inda…

2021

business.industryImmunologyFixed-dose combinationmedicineImmunology and AllergyIndacaterolMometasone furoateOnce dailyPharmacologybusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ ind…

2021

Once-daily (o.d.) fixed-dose combinations of mometasone furoate/indacaterol acetate (MF/IND) and mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY), both delivered via the Breezhaler® device, are approved for the maintenance treatment of asthma. Across these fixed-dose combinations, while the doses of bronchodilators remain the same, the nominal doses of mometasone furoate in micrograms differ. This article presents the steps followed in bridging the mometasone furoate doses at the corresponding dose strengths in the mometasone furoate formulation delivered via the Twisthaler® and mometasone furoate/indacaterol acetate and mometasone furoate/indacaterol acetate/glyco…

Pulmonary and Respiratory Medicinemedicine.drug_classMometasone furoateQuinolonesPharmacologyFixed doseAdministration InhalationHumansMedicinePharmacology (medical)In patientGlycopyrronium bromideAsthmabusiness.industryBiochemistry (medical)medicine.diseaseGlycopyrrolateAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeIndansIndacaterolCorticosteroidOnce dailybusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct